Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 TG01/QS-21 vaccine in KRAS/NRAS-mutated high-risk smoldering or active multiple myeloma
2022-502275-39-00Phase 2Authorised
- Sponsor
- Oslo University Hospital
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of apricoxib in multiple myeloma (MM) and smoldering multiple myeloma (SMM), sponsored by Oslo University Hospital. Planned start Dec 2022; status: authorised.
02
Drugs
apricoxib
03
Conditions
multiple myeloma (MM)smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on 2022-502275-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502275-39-00.